4-(3-bromo-propyl)-benzonitrile | 83101-14-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(3-bromo-propyl)-benzonitrile
• 英文别名: γ-(4-Cyanphenyl)propylbromid；4-(3-bromopropyl)benzonitrile；4-(3-Brom-propyl)-benzonitril；1-(3-bromopropyl)-4-cyanobenzene
• CAS: 83101-14-8
• 化学式: C₁₀H₁₀BrN
• 分子量: 224.1
• InChiKey: GSQHPAQTFSHMPZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-(3-bromo-propyl)-benzonitrile 在 C₂H₂ONa 作用下， 以 乙醇 为溶剂， 反应 5.0h， 生成 5-(4-Cyanphenyl)-2-β-naphthylsulfonylaminovaleriansaeureanilid
  参考文献：
  名称：

  Vieweg; Wagner, Pharmazie, 1982, vol. 37, # 3, p. 178 - 182

  摘要：

  DOI：
• 作为产物：
  描述：

  4-(3-溴丙基)苯甲酸 在 氯化亚砜 、 苯 作用下， 生成 4-(3-bromo-propyl)-benzonitrile
  参考文献：
  名称：

  Basic-alkyl Esters of p-(Aminoalkyl)-benzoic Acids. I

  摘要：

  DOI：

  10.1021/ja01252a006

文献信息

• [EN] GLUCOSE TRANSPORT INHIBITORS<br/>[FR] INHIBITEURS DE TRANSPORT DU GLUCOSE
  申请人：BAYER PHARMA AG

  公开号：WO2015091428A1

  公开（公告）日：2015-06-25

  The present invention relates to chemical compounds that selectively inhibit glucose transporter 1 (GLUT1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.

  本发明涉及选择性抑制葡萄糖转运蛋白1（GLUT1）的化合物，涉及制备该类化合物的方法，包括含有该类化合物的药物组合物和药物组合物，以及利用该类化合物制造用于治疗或预防疾病的药物组合物的用途，还涉及在制备该类化合物中有用的中间体化合物。
• Silacyclohexane compounds, preparation thereof, liquid crystal
  申请人：Shin-Etsu Chemical Co., Ltd.

  公开号：US05665271A1

  公开（公告）日：1997-09-09

  Silacyclohexane compounds of the following formula (I) or (II) along with intermediate compounds therefor are described ##STR1## wherein R is an organic residue, one of ##STR2## represents a trans-1-sila-1,4-cyclohexylene group or trans-4-sila-1,4-cyclohexylene group having a substituent of H, F, Cl or CH.sub.3, and the other represents a trans-1,4-cyclohexylene group, or such a trans-1-sila-1,4-cyclohexylene group or trans-4-sila-1,4-cyclohexylene group as defined above, n is 0 or 1, L.sub.1 represents H or F, L.sub.2 represents H, F or Cl, and Z represents CN, F, Cl or an organic residue, and ##STR3## The processes for preparing the compounds (I) and (II) are also described along with liquid crystal compositions comprising the compounds and the liquid crystal devices comprising the compositions.

  以下是化学方程式的中文翻译： 描述了具有以下化学式（I）或（II）的硅环己烷化合物以及其中间体化合物##STR1##其中R是有机残基，##STR2##中的一个代表具有H、F、Cl或CH.sub.3取代基的反式-1-硅-1,4-环己烯基或反式-4-硅-1,4-环己烯基，另一个代表反式-1,4-环己烯基，或者如上定义的反式-1-硅-1,4-环己烯基或反式-4-硅-1,4-环己烯基，n为0或1，L.sub.1代表H或F，L.sub.2代表H、F或Cl，Z代表CN、F、Cl或有机残基，以及##STR3##还描述了制备化合物（I）和（II）的过程，以及包括这些化合物的液晶组合物和包括这些组合物的液晶器件。
• [EN] NOVEL OXABISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS<br/>[FR] NOUVEAUX COMPOSES D'OXABISPIDINE ET LEUR UTILISATION DANS LE TRAITEMENT D'ARYTHMIES CARDIAQUES
  申请人：ASTRAZENECA AB

  公开号：WO2005123747A1

  公开（公告）日：2005-12-29

  There is provided compounds of formula I, wherein R1, R2, R4, R41 to R46, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.

  提供了具有公式I的化合物，其中R1、R2、R4、R41到R46、A、B和G的含义如描述中所示，在预防和治疗心律失常，特别是心房和心室心律失常方面是有用的。
• EP4 receptor selective agonists in the treatment of osteoporosis
  申请人：——

  公开号：US20020065308A1

  公开（公告）日：2002-05-30

  This invention is directed to EP4 receptor selective prostaglandin agonists of the Formula I, 1 wherein R 2 , X, Z and Q are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds. This invention is also directed to methods of treating conditions which present with low bone mass, particularly osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis, or prosthetic ingrowth in a mammal comprising administering those compounds.

  这项发明针对公式I中的EP4受体选择性前列腺素激动剂，其中R2、X、Z和Q的定义如规范中所述。该发明还涉及含有这些化合物的药物组合物。该发明还涉及治疗低骨密度症状的方法，特别是骨质疏松症、虚弱、骨折、骨缺损、儿童特发性骨量减少、牙槽骨丧失、下颌骨丧失、骨折、骨切开术、与牙周炎相关的骨丧失或哺乳动物体内假体生长中的骨丧失，包括给予这些化合物。
• Reductive activation of arenes 22. Reactions of the terephthalonitrile radical anion and dianion with α,ω-dibromoalkanes. New evidence for the charge transfer complex as a key intermediate in the reactions of the dianion
  作者：E. V. Panteleeva、M. Yu. Lukyanova、L. M. Pokrovsky、V. D. Shteingarts

  DOI：10.1007/s11172-007-0168-z

  日期：2007.6

  suggest that reactions of the dianion with intermediate 4-(ω-bromoalkyl)benzonitriles proceed more rapidly than those with the starting α,ω-dibromoalkanes. This was confirmed by competitive reactions of the dianion with 4-(ω-bromoalkyl)benzonitriles and the corresponding alkyl bromides. To explain such a ratio of the reaction rates, a mechanism was proposed for the reaction of the dianion with 4-(ω-

  对苯二甲腈自由基阴离子与 α,ω-二溴烷烃 Br(CH2)nBr (n = 3–5) 反应的主要产物是 4-(ω-溴烷基) 苄腈。对苯二甲腈二阴离子的类似反应主要产生 α,ω-双（4-氰基苯基）烷烃。这两种转化都是方便的一步途径，否则不易获得化合物，这些化合物作为多功能构建块很有价值。烷基化的结果表明，二价阴离子与中间体 4-（ω-溴烷基）苄腈的反应比与起始 α,ω-二溴烷烃的反应进行得更快。这通过二价阴离子与 4-(ω-溴烷基) 苄腈和相应的烷基溴的竞争反应得到证实。为了解释反应速率的这种比率，提出了二价阴离子与 4-(ω-溴代烷基)苄腈反应的机理。根据这种机制，电荷转移复合物是关键的反应中间体。